Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.

Untitled Document

With the sustained protection of HEMLIBRA,1–3 life can be beautifully spontaneous

Treated annualised bleed rate (ABR) was 1.5 for HEMLIBRA every week (1.5 mg/kg/QW) and 1.3 for HEMLIBRA every 2 weeks (3.0 mg/kg/Q2W) vs. 38.2 for episodic FVIII. Sustained mean trough plasma concentrations of HEMLIBRA were achieved across all doses (open-label studies).1–3

Discover HEMLIBRA

Efficacy

Safety

Dosing


HEMLIBRA delivers sustained protection,1–3 with a half-life of weeks, not hours1

 

Hemlibra protects

HEMLIBRA

protects

patients, with 82% maintaining zero treated bleeds after 144 weeks.4

Hemlibra protects

HEMLIBRA

supports

patients, with many no longer experiencing joint pain, swelling, painful movements or difficulty walking.5

Hemlibra is preferred

HEMLIBRA

is preferred

by patients, with >90% favouring it over their prior FVIII prophylaxis.6


Experience with HEMLIBRA is growing

Learn about real-world effectiveness of HEMLIBRA, as evaluated by the UK Haemophilia Centre Doctors’ Organisation (UKHCDO).

UK experience

Watch experts discuss HEMLIBRA at the latest global congresses and symposia.

Congresses

Find support and information for your patients that have been prescribed HEMLIBRA.

HEMLIBRA resource centre


▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. As HEMLIBRA® is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.


For full details please refer to the HEMLIBRA® Summary of Product Characteristics.


ABR, annualised bleed rate; FVIII, Factor VIII; MOA, mechanism of action; QW, every week; Q2W, every 2 weeks; UKHCDO, UK Haemophilia Centre Doctors’ Organisation.


References:

  1. HEMLIBRA Summary of Product Characteristics.
  2. Mahlangu J et al. N Engl J Med 2018;379:811-22.
  3. Oldenburg J et al. N Engl J Med 2017;377:809-18.
  4. Callaghan M et al. Blood 2021;137:2231–42.
  5. von Mackensen S et al. Haemophilia 2020;26:1019–30.
  6. Kempton C et al. Haemophilia 2021;27:221–28.

M-GB-00004678
Date of preparation: September 2021